Pieris Pharmaceuticals
Quarterly Financials
| Values in thousands | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
|---|---|---|---|---|
Revenue | $0 | $0 | $53 | $1,299 |
Gross Profit | -751 | 83 | -3,155 | |
EBITDA | -3,135 | -4,177 | -5,303 | -5,705 |
EBIT | -4,176 | -5,273 | -6,181 | |
Net Income | -2,887 | -3,590 | -4,892 | -4,584 |
Net Change In Cash | 0 | 0 | 53 | 1,299 |
Free Cash Flow | 146 | -1,480 | -6,996 | -19,656 |
Cash | 19,363 | 19,731 | 19,084 | 17,396 |
Basic Shares | 1,320 | 1,299 | 1,237 | 1,237 |
Annual Financials
| Values in thousands | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|
Revenue | $42,810 | $25,902 | $31,418 | $29,323 |
Gross Profit | 1,009 | 23,122 | 29,050 | -17,208 |
EBITDA | -22,762 | -30,497 | -43,370 | -31,610 |
EBIT | -24,543 | -33,277 | -45,738 | -33,737 |
Net Income | -24,543 | -31,253 | -43,366 | -37,230 |
Net Change In Cash | 42,810 | 25,902 | 31,418 | 29,323 |
Cost of Revenue | 50,518 | 3,431 | ||
Free Cash Flow | -53,990 | -60,973 | -8,609 | -48,622 |
Cash | 17,396 | 38,635 | 117,764 | 70,436 |
Basic Shares | 1,125 | 927 | 806 | 681 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-09-30 | -$2.18 |
2024-06-30 | -$2.76 |
2024-03-31 | -$3.95 |
2023-12-31 | -$3.70 |
